- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01648153
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM (T2DM)
A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but <9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.
Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Cambridge, Regno Unito, CB2 2GG
- GSK Investigational Site
-
Dundee, Regno Unito, DD1 9SY
- GSK Investigational Site
-
-
Warwickshire
-
Birmingham, Warwickshire, Regno Unito, B15 2TT
- GSK Investigational Site
-
-
-
-
-
Alicante, Spagna, 03004
- GSK Investigational Site
-
Alzira/Valencia, Spagna, 46600
- GSK Investigational Site
-
Granada, Spagna, 18012
- GSK Investigational Site
-
La Roca del Valles (Barcelona), Spagna, 08430
- GSK Investigational Site
-
Lleida, Spagna, 25198
- GSK Investigational Site
-
Madrid, Spagna, 28046
- GSK Investigational Site
-
Madrid, Spagna, 28034
- GSK Investigational Site
-
Malaga, Spagna, 29010
- GSK Investigational Site
-
Málaga, Spagna, 29010
- GSK Investigational Site
-
Petrer, Alicante, Spagna, 03610
- GSK Investigational Site
-
Santander, Spagna, 39008
- GSK Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
- Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
- HbA1c levels ≥ 7.0 % and ≤ 9.5%; at Screening.
- On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
- Fasting plasma glucose level < 13.3 mmol/L (240 mg/dL) at screening.
- Obese with BMI ≥ 30 kg/m2, and < 40 kg/m2.
- Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
- The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
A female subject is eligible to participate if she is of:
- Non-childbearing potential
- Child-bearing potential and agrees to use an acceptable form of contraception.
- Male subjects must agree to use one of the contraception methods listed
- ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Single or Average QTc, QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
- Use of anti-inflammatory drugs including corticosteroids, chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
- Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
- History of malignancy or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
- History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
- Creatinine clearance less than 60ml/min
- Screens positive of Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV)
- History of a severe allergic reaction, anaphylaxis or immunodeficiency.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- History of regular alcohol consumption within 6 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Subject has received a live attenuated vaccine(s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: GSK1070806 0.25mg/kg
TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Comparatore attivo: GSK1070806 5mg/kg
Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Comparatore placebo: Placebo (Saline)
Two IV administrations of saline 4 weeks apart
|
To compare the efficacy and biomarker changes between placebo and active groups
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT)
Lasso di tempo: Up to 85 days after the first does
|
To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM
|
Up to 85 days after the first does
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive
Lasso di tempo: Up to 85 days after the first dose
|
To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM
|
Up to 85 days after the first dose
|
AUC(0-τ)
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Serum levels of free IL-18 and drug bound IL 18
Lasso di tempo: Up to 210 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.
|
Up to 210 days after the first dose
|
Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides
Lasso di tempo: Up to 85 days after the first dose
|
To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease
|
Up to 85 days after the first dose
|
Change from baseline in waist circumference and BMI
Lasso di tempo: Up to 85 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM
|
Up to 85 days after the first dose
|
Cmax
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Tmax
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
after the second dose λz
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
t1/2
Lasso di tempo: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 116378
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Dati/documenti di studio
-
Specifica del set di dati
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di segnalazione del caso annotato
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocollo di studio
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Piano di analisi statistica
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Set di dati del singolo partecipante
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di consenso informato
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Rapporto di studio clinico
Identificatore informazioni: 116378Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su GSK1070806
-
GlaxoSmithKlineCompletatoDermatite, atopicaStati Uniti, Canada
-
GlaxoSmithKlineReclutamentoDermatite, atopicaCanada, Spagna, Cina, Stati Uniti, Argentina, Polonia, Corea, Repubblica di, Panama, Giappone, Bulgaria, Cechia, Francia, Germania, Grecia, Italia, Messico, Tailandia
-
Cambridge University Hospitals NHS Foundation TrustSconosciuto
-
GlaxoSmithKlineCompletatoMalattie infiammatorie intestinaliRegno Unito
-
GlaxoSmithKlineCompletato
-
University of BirminghamGlaxoSmithKline; University Hospital BirminghamCompletato
-
Seoul National University HospitalNon ancora reclutamentoIpotensione | Complicanze intraoperatorie | Ipotensione neonatale
-
GlaxoSmithKlineTerminatoTrapianto di rene (Status Post)Regno Unito, Spagna